New York, USA - September 29, 2025 - The intricacy underlying neurological disorders emerges from a multitude of pathological processes. Traditional two-dimensional cell models and animal studies fall short in faithfully mimicking the human nervous system, often leading to high attrition rates of candidate drugs in clinical trials.
"Animal experiments are, of course, invaluable, but they only enable appreciation of the basics of pharmacology; they do not even attempt to simulate the human physiological system. Instead, they rely on abstractions. Our efforts in drug discovery for nervous system disorders utilizing 3D neurological models constructively augment the predictive power by simulating the functionality of actual human tissues," profoundly states a Creative Biolabs expert.
Creative Biolabs' 3D Spheroid Models
The last decade in clinical research has seen the emergence of 3D spheroid models for neurological disorders as a remarkable advancement in novel drug discovery systems. 3D spheroid models, in contrast to traditional 2D systems, encase neural cells in more elaborate structures, which permits the representation of more intricate and complex cellular interactions and structures typical in the progression of pathologies.
These models possess the distinct ability to record and visualize the behavior of cells in a microenvironment and more closely approximate primary human brain cells in morphology and function. Researchers can further improve the models by adding astrocytes or pericytes to better mimic the blood-brain barrier (BBB) and the neural microenvironment.
The applications of 3D spheroid models are wide-ranging:
Drug Screening: Reducing spending on ineffective medications while improving the predictive accuracy of toxicity and efficacy evaluations.
Metabolism and Toxicity Evaluation: Reduces clinical adverse events by realistically reflecting in vivo drug metabolism pathways.
Disease Mechanism Studies: Helps scientists unravel the cellular and molecular basis of many neurological disorders and identify potential new treatment targets.
Therapeutic Validation: Providing clinically relevant environments to validate novel drugs and treatment strategies.
The expert commented, "We are strong believers that 3D spheroid models are tools that close the gap between laboratory research and clinical application. These models are far more than experimental tools, and we see enormous value in the use of such models in screening drugs and in personalized medicine."
Brain Endothelial Cell Monoculture Models
BBB is a significant barrier to the advancement of drug development in neurology. More than 98% of therapeutic molecules fail to penetrate the BBB due to their intrinsic molecular properties, leading to the early elimination of many potential treatments.
To address this, Creative Biolabs has developed a brain endothelial cell monoculture model that provides an in vitro platform for drug research. This model is built on a Transwell system and for the study of drug permeability and barrier integrity. Techniques such as TEER measurements and fluorescent labeling are applied to assess BBB function, while integration with 3D culture and organ-on-a-chip technologies further enhances physiological relevance.
The expert noted, "While important for the central nervous system, the blood-brain barrier is also a barrier to drug discovery. Our brain endothelial cell model provides researchers with a more accurate way to evaluate drug candidates before clinical trials, which should improve the chances of success for CNS drugs that reach the clinic."
About Creative Biolabs
Creative Biolabs has extended the 3D biology platform to include spheroid and brain endothelial cell models to comprehensively support pharmaceutical companies and research institutions focused on neurological drug discovery and development.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/3d-biology
